{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T01:43:52Z","timestamp":1782956632348,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The 90th Anniversary of Chulalongkorn University Scholarship, Ratchadapiseksompotch Fund"},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]},{"name":"Ratchadapiseksompotch Fund, Faculty of Medicine, Chulalongkorn University","award":["RA67\/030"],"award-info":[{"award-number":["RA67\/030"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-51288-2","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T07:54:59Z","timestamp":1777708499000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase 1 dose-finding study of topical neostigmine ophthalmic solution for alleviating myasthenic ptosis"],"prefix":"10.1038","volume":"16","author":[{"given":"Chuthamas","family":"Ongprakobkul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supanut","family":"Apinyawasisuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supharat","family":"Jariyakosol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pajaree","family":"Chariyavilaskul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kornvalee","family":"Meesilpavikkai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuda","family":"Chongpison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"51288_CR1","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.ophtha.2015.03.010","volume":"122","author":"L Nagia","year":"2015","unstructured":"Nagia, L., Lemos, J., Abusamra, K., Cornblath, W. T. & Eggenberger, E. R. Prognosis of ocular myasthenia gravis: retrospective multicenter analysis. Ophthalmology 122, 1517\u20131521 (2015).","journal-title":"Ophthalmology"},{"key":"51288_CR2","doi-asserted-by":"publisher","first-page":"101040","DOI":"10.1016\/j.disamonth.2020.101040","volume":"66","author":"E Avdagic","year":"2020","unstructured":"Avdagic, E. & Phelps, P. O. Eyelid ptosis (blepharoptosis) for the primary care practitioner. Dis. Mon. 66, 101040 (2020).","journal-title":"Dis. Mon"},{"key":"51288_CR3","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s00415-019-09631-3","volume":"267","author":"MP Giannoccaro","year":"2020","unstructured":"Giannoccaro, M. P. et al. Sensitivity and specificity of single-fibre EMG in the diagnosis of ocular myasthenia varies accordingly to clinical presentation. J. Neurol. 267, 739\u2013745 (2020).","journal-title":"J. Neurol."},{"key":"51288_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.ncl.2018.01.010","volume":"36","author":"M Pasnoor","year":"2018","unstructured":"Pasnoor, M., Dimachkie, M. M., Farmakidis, C. & Barohn, R. J. Diagnosis of myasthenia gravis. Neurol. Clin. 36, 261\u2013274 (2018).","journal-title":"Neurol. Clin."},{"key":"51288_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.11.004","volume":"218","author":"C Provenzano","year":"2010","unstructured":"Provenzano, C., Marino, M., Scuderi, F., Evoli, A. & Bartoccioni, E. Anti-acetylcholinesterase antibodies associate with ocular myasthenia Gravis. J. Neuroimmunol. 218, 102\u2013106 (2010).","journal-title":"J. Neuroimmunol."},{"key":"51288_CR6","unstructured":"Neely, G. A., Sabir, S. & Kohli, A. Neostigmine StatPearls. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK470596\/ (2023)."},{"key":"51288_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3341\/kjo.2011.25.1.1","volume":"25","author":"HS Roh","year":"2011","unstructured":"Roh, H. S., Lee, S. Y. & Yoon, J. S. Comparison of clinical manifestations between patients with ocular myasthenia gravis and generalized myasthenia gravis. Korean J. Ophthalmol. 25, 1\u20137 (2011).","journal-title":"Korean J. Ophthalmol."},{"key":"51288_CR8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.nmd.2006.05.006","volume":"16","author":"M Benatar","year":"2006","unstructured":"Benatar, M. A systematic review of diagnostic studies in myasthenia gravis. Neuromuscul. Disord. 16, 459\u2013467 (2006).","journal-title":"Neuromuscul. Disord"},{"key":"51288_CR9","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.nmd.2022.09.002","volume":"32","author":"L Remijn-Nelissen","year":"2022","unstructured":"Remijn-Nelissen, L., Verschuuren, J. & Tannemaat, M. R. The effectiveness and side effects of pyridostigmine in the treatment of myasthenia gravis: a cross-sectional study. Neuromuscul. Disord. 32, 790\u2013799 (2022).","journal-title":"Neuromuscul. Disord"},{"key":"51288_CR10","doi-asserted-by":"publisher","first-page":"30847","DOI":"10.1038\/s41598-025-16328-3","volume":"15","author":"C Ongprakobkul","year":"2025","unstructured":"Ongprakobkul, C. et al. Safety and effect of topical neostigmine ophthalmic solution in animal models. Sci. Rep. 15, 30847 (2025).","journal-title":"Sci. Rep."},{"key":"51288_CR11","unstructured":"OECD. Test No. 405: acute eye irritation\/corrosion, OECD guidelines for the testing of chemicals, Sect.\u00a0 4. OECD iLibrary. (2021). https:\/\/www.oecd-ilibrary.org\/docserver\/9789264185333-en.pdf?expires=1675048604&id=id&accname=guest&checksum=BEA0A37912AFCFEF7DDDC5639CF4F39B"},{"key":"51288_CR12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1093\/jnci\/djp079","volume":"101","author":"C Le Tourneau","year":"2009","unstructured":"Le Tourneau, C., Lee, J. J. & Siu, L. L. Dose escalation methods in phase I cancer clinical trials. J. Natl. Cancer Inst. 101, 708\u2013720 (2009).","journal-title":"J. Natl. Cancer Inst."},{"key":"51288_CR13","unstructured":"U.S. department of health and human. Common terminology criteria for adverse events (CTCAE) version 5.0. (2017). https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_8.5x11.pdf"},{"key":"51288_CR14","first-page":"004","volume":"S11","author":"MA Salih","year":"2012","unstructured":"Salih, M. A. et al. Ocular neostigmine drops for diagnosing myasthenia gravis. J. Neurol. Neurophysiol. S11, 004 (2012).","journal-title":"J. Neurol. Neurophysiol."},{"key":"51288_CR15","unstructured":"National Research Council (US) Panel on Anticholinesterase Chemicals. Possible long-term health effects of short-term exposure to chemical agents: volume 1 anticholinesterases and anticholinergics. National Academies Press (US). (1982). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK217772\/"},{"key":"51288_CR16","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1007\/s00417-021-05297-8","volume":"259","author":"M Nejad","year":"2021","unstructured":"Nejad, M. et al. Effect of over-the-counter brimonidine tartrate 0.025% ophthalmic solution on pupil size in healthy adults. Graefes Arch. Clin. Exp. Ophthalmol. 259, 3333\u20133338 (2021).","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"51288_CR17","unstructured":"Andrade, O. A. & Zafar, G. A. Physostigmine (eds) (Archived). StatPearls. https:\/\/www-ncbi-nlm-nih-gov.cumL1.md.chula.ac.th\/books\/NBK545261\/ (2023)."},{"key":"51288_CR18","doi-asserted-by":"crossref","unstructured":"Day, A. C., Nolan, W., Malik, A. N., Viswanathan, A. C. & Foster, P. J. Pilocarpine induced acute angle closure. BMJ Case Rep. 2012, bcr0120125694 (2012).","DOI":"10.1136\/bcr.01.2012.5694"},{"key":"51288_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/S0161-6420(79)35529-4","volume":"86","author":"H Beasley","year":"1979","unstructured":"Beasley, H. & Fraunfelder, F. T. Retinal detachments and topical ocular miotics. Ophthalmology 86, 95\u201398 (1979).","journal-title":"Ophthalmology"},{"key":"51288_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ajo.2022.05.011","volume":"242","author":"H Al-Khersan","year":"2022","unstructured":"Al-Khersan, H., Flynn, H. W. Jr. & Townsend, J. H. Retinal detachments associated with topical pilocarpine use for presbyopia. Am. J. Ophthalmol. 242, 52\u201355 (2022).","journal-title":"Am. J. Ophthalmol."},{"key":"51288_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0039-6257(94)90194-5","volume":"39","author":"DA Weinberg","year":"1994","unstructured":"Weinberg, D. A., Lesser, R. L. & Vollmer, T. L. Ocular myasthenia: a protean disorder. Surv. Ophthalmol. 39, 169\u2013210 (1994).","journal-title":"Surv. Ophthalmol."},{"key":"51288_CR22","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1001\/jamaophthalmol.2020.3833","volume":"138","author":"EA Bradley","year":"2020","unstructured":"Bradley, E. A. & Bradley, D. J. Oxymetazoline for ptosis. JAMA Ophthalmol. 138, 1176\u20131177 (2020).","journal-title":"JAMA Ophthalmol."},{"key":"51288_CR23","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1001\/jamaophthalmol.2020.3812","volume":"138","author":"CB Slonim","year":"2020","unstructured":"Slonim, C. B. et al. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 138, 1168\u20131175 (2020).","journal-title":"JAMA Ophthalmol."},{"key":"51288_CR24","unstructured":"American Academy of Ophthalmology. 2022\u20132023 Basic and clinical science course, Sect.\u00a0 2: fundamentals and principles of ophthalmology Vol. 26 (American Academy of Ophthalmology, 2022)."},{"key":"51288_CR25","first-page":"e36351","volume":"15","author":"M Taha","year":"2023","unstructured":"Taha, M., Li, Y. & Morren, J. Oxymetazoline hydrochloride eye-drops as treatment for myasthenia gravis-related ptosis: a description of two cases. Cureus 15, e36351 (2023).","journal-title":"Cureus"},{"key":"51288_CR26","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/OPX.0000000000001800","volume":"98","author":"J Cooper","year":"2021","unstructured":"Cooper, J. & Yang, D. Case report: treatment of myasthenic ptosis with topical ocular oxymetazoline. Optom. Vis. Sci. 98, 1317\u20131320 (2021).","journal-title":"Optom. Vis. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51288-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51288-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51288-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:48:47Z","timestamp":1782953327000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-51288-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["51288"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-51288-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"9 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20311"}}